CA2477328A1 - Pyridyl tricyclic compounds as farnesyl protein transferase inhibitors and antitumor agents - Google Patents

Pyridyl tricyclic compounds as farnesyl protein transferase inhibitors and antitumor agents Download PDF

Info

Publication number
CA2477328A1
CA2477328A1 CA002477328A CA2477328A CA2477328A1 CA 2477328 A1 CA2477328 A1 CA 2477328A1 CA 002477328 A CA002477328 A CA 002477328A CA 2477328 A CA2477328 A CA 2477328A CA 2477328 A1 CA2477328 A1 CA 2477328A1
Authority
CA
Canada
Prior art keywords
group
substituted
alkyl
compound
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002477328A
Other languages
English (en)
French (fr)
Inventor
Hugh Y. Zhu
F. George Njoroge
Alan B. Cooper
Timothy J. Guzi
Dinanath F. Rane
Keith P. Minor
Ronald J. Doll
Viyyoor Moopil Girijavallabhan
Bama Santhanam
Patrick A. Pinto
Bancha Vibulbhan
Kartik M. Keertikar
Carmen S. Alvarez
John J. Baldwin
Ge Li
Chia-Yu Huang
Ray A. James
W. Robert Bishop
James J-S Wang
Jagdish A. Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Pharmacopeia LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/085,896 external-priority patent/US20030229099A1/en
Application filed by Individual filed Critical Individual
Publication of CA2477328A1 publication Critical patent/CA2477328A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002477328A 2002-02-27 2003-02-25 Pyridyl tricyclic compounds as farnesyl protein transferase inhibitors and antitumor agents Abandoned CA2477328A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/085,896 2002-02-27
US10/085,896 US20030229099A1 (en) 2000-08-30 2002-02-27 Novel farnesyl protein transferase inhibitors as antitumor agents
US10/325,896 US7342016B2 (en) 2000-08-30 2002-12-19 Farnesyl protein transferase inhibitors as antitumor agents
US10/325,896 2002-12-19
PCT/US2003/005479 WO2003072549A1 (en) 2002-02-27 2003-02-25 Farnesyl protein transferase inhibitors as antitumor agents

Publications (1)

Publication Number Publication Date
CA2477328A1 true CA2477328A1 (en) 2003-09-04

Family

ID=27767345

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002477328A Abandoned CA2477328A1 (en) 2002-02-27 2003-02-25 Pyridyl tricyclic compounds as farnesyl protein transferase inhibitors and antitumor agents

Country Status (19)

Country Link
US (1) US7342016B2 (OSRAM)
EP (1) EP1492772A1 (OSRAM)
JP (1) JP2005525356A (OSRAM)
KR (1) KR20040098004A (OSRAM)
CN (1) CN100537542C (OSRAM)
AR (1) AR039557A1 (OSRAM)
AU (1) AU2003215389B2 (OSRAM)
BR (1) BR0308071A (OSRAM)
CA (1) CA2477328A1 (OSRAM)
CO (1) CO5611194A2 (OSRAM)
IL (1) IL163673A0 (OSRAM)
MX (1) MXPA04008303A (OSRAM)
NO (1) NO20044053L (OSRAM)
NZ (1) NZ534809A (OSRAM)
PE (1) PE20031038A1 (OSRAM)
PL (1) PL372335A1 (OSRAM)
RU (1) RU2004128465A (OSRAM)
TW (1) TW200303867A (OSRAM)
WO (1) WO2003072549A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ621449A (en) * 2003-05-30 2015-07-31 Genentech Inc Treatment with anti-vegf antibodies
ATE417041T1 (de) * 2003-08-07 2008-12-15 Schering Corp Neue farnesylproteintransferaseinhibitoren als antitumormittel
CA2568524A1 (en) * 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
JP2008501758A (ja) 2004-06-09 2008-01-24 グラクソ　グループ　リミテッド ピロロピリジン誘導体
EP1833481A1 (en) 2004-12-14 2007-09-19 Schering Corporation Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
AU2005319182A1 (en) * 2004-12-21 2006-06-29 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
CA2637572A1 (en) * 2006-01-19 2007-07-26 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors
US20080090242A1 (en) * 2006-09-29 2008-04-17 Schering Corporation Panel of biomarkers for prediction of fti efficacy
MY183404A (en) * 2006-12-19 2021-02-18 Genentech Inc Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
WO2010006432A1 (en) * 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
US8975247B2 (en) 2009-03-18 2015-03-10 The Board Of Trustees Of The Leland Stanford Junion University Methods and compositions of treating a flaviviridae family viral infection
US9227962B2 (en) 2013-03-13 2016-01-05 Boston Biomedical, Inc. Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
CN105777646A (zh) * 2016-04-08 2016-07-20 西南科技大学 一种新的5-碘-2-苯基-1-甲基咪唑的制备方法
CN111454329A (zh) * 2020-04-07 2020-07-28 哈尔滨师范大学 一种具有抗癌活性的异茚哚酮桥连环九肽及其制备方法
WO2023071601A1 (zh) * 2021-10-28 2023-05-04 天津市昕晨投资发展有限公司 地氯雷他定衍生物、其制备方法及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US5393890A (en) 1988-06-02 1995-02-28 Ajinomoto Co., Inc. Piperidine derivatives and hypotensives containing the same
AU8854091A (en) 1990-10-10 1992-05-20 Schering Corporation Bis-benzo cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US6075025A (en) * 1993-10-15 2000-06-13 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5721236A (en) 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
CZ292791B6 (cs) * 1995-12-22 2003-12-17 Schering Corporation Tricyklické amidy, které se používají pro inhibici G-proteinové funkce a k léčení proliferativních onemocnění
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6071907A (en) 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
AU4337497A (en) * 1996-09-13 1998-04-02 Schering Corporation Tricyclic compounds useful as fpt inhibitors
EP0929544B1 (en) 1996-09-13 2004-11-10 Schering Corporation Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
AU8253598A (en) 1997-06-17 1999-01-04 Schering Corporation Novel n-substituted urea inhibitors of farnesyl-protein transferase
EP1156046A1 (en) 1997-06-17 2001-11-21 Schering Corporation Benzo(5,6)cyclohepta(1,2-B)pyridine derivatives for the inhibition of farnesyl protein transferase
KR100640672B1 (ko) 1997-06-17 2006-11-02 파마코페이아 드럭 디스커버리, 인크. 파르네실 단백질 트랜스퍼라제의 억제에 유용한 벤즈피리도 사이클로헵탄 화합물 및 이를 포함하는 약제학적 조성물
IL133393A0 (en) 1997-06-17 2001-04-30 Schering Corp Novel tricyclic sulfonamide inhibitors of farnesyl-protein transferase
US5925648A (en) 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
AR021718A1 (es) 1998-12-18 2002-07-31 Schering Corp Inhibidores de transferasa de proteina farnesilo.
ATE293622T1 (de) 1998-12-18 2005-05-15 Schering Corp Farnesyl protein transferase inhibitoren
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
SI1255537T1 (sl) 2000-02-04 2006-10-31 Janssen Pharmaceutica Nv Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
AR033680A1 (es) 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
ATE417041T1 (de) * 2003-08-07 2008-12-15 Schering Corp Neue farnesylproteintransferaseinhibitoren als antitumormittel

Also Published As

Publication number Publication date
CN100537542C (zh) 2009-09-09
PL372335A1 (en) 2005-07-11
RU2004128465A (ru) 2005-09-27
JP2005525356A (ja) 2005-08-25
NZ534809A (en) 2007-12-21
CO5611194A2 (es) 2006-02-28
AU2003215389A1 (en) 2003-09-09
BR0308071A (pt) 2004-12-21
AR039557A1 (es) 2005-02-23
PE20031038A1 (es) 2004-01-10
NO20044053L (no) 2004-11-26
US20040122018A1 (en) 2004-06-24
CN1630641A (zh) 2005-06-22
TW200303867A (en) 2003-09-16
WO2003072549A1 (en) 2003-09-04
EP1492772A1 (en) 2005-01-05
IL163673A0 (en) 2005-12-18
US7342016B2 (en) 2008-03-11
MXPA04008303A (es) 2005-11-23
KR20040098004A (ko) 2004-11-18
AU2003215389B2 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
AU711238B2 (en) Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
AU2003215389B2 (en) Farnesyl protein transferase inhibitors as antitumor agents
TW200948799A (en) Novel compounds that are ERK inhibitors
US20030229099A1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
EP1453513A1 (en) Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
JP2005525356A5 (OSRAM)
AU2001288451C1 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
EP1660477B1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
AU2001288451A1 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
CA2591123A1 (en) Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
CN101317845B (zh) 一类6-芳基取代吡啶类化合物的药物用途
US5945430A (en) Aminooxyamide tricyclic inhibitors of farnesyl-protein transferase
US20060205755A1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
KR20010013944A (ko) 파네실 단백질 트랜스퍼라제의 억제에 유용한벤조(5,6)사이클로헵타(1,2-ｂ)피리딘 유도체
HK1087122B (en) Novel farnesyl protein transferase inhibitors as antitumor agents
AU2007202115A1 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued